23 February 2021 - - The first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US, South Korea-based LG Chem Life Sciences said.

LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd, a clinical-stage biotechnology company based in Nanjing, China.

LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.

According to the company, LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis. The phase 1 study is currently being conducted within the US and approximately 64 subjects are expected to be enrolled.

LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally.

LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.

TransThera Biosciences is a clinical-stage biotechnology company focused on developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation.

TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases.